|Base-case costs estimates ($, year 2012 values) and utilities|
|Parameter||Median||Range||Description and references|
|Cost of EGFR genotyping per patient||507.9||381–634.9||Local charge|
|Cost of gefitinib per 250 mg ($)||77.8||38.9–77.8*||Local charge|
|Cost of follow-up per unit ($)||55.6||41.7–69.4|||
|Cost of 2nd-line chemotherapy per cycle ($)||2352.7||1921.1–4383.3||Calculation|
|Cost of palliative care in end-of-life treatment ($)||3664.3||21.4–48750.2||Calculation|
|Cost of supportive care per cycle ($)||337.5||158.7–793.7||Calculation|
|Cost of SAEs in platinum-based chemotherapy per cycle ($)||507.4||189.7–825.0||Calculation|
|Expenditures of SAEs in maintenance treatment per cycle|
|Cost of SAEs in Gefitinib strategy per cycle ($)||Formula#||Calculation|
|Utility of PFS||0.65||0.26–0.87|||
|Utility of OS||0.47||0.19–0.58|||
* The range was assumed for a one-way sensitivity analysis.
# Formula: Cost of SAEs in platinum-based chemotherapy per cycle × Cumulative probability of SAEs in maintenance strategy / Cumulative probability of SAEs in platinum-based chemotherapy.
Zhu et al.
Zhu et al. BMC Cancer 2013 13:39 doi:10.1186/1471-2407-13-39